XHKG
6185
Market cap1.39bUSD
Jul 10, Last price
35.75HKD
1D
2.29%
1Q
20.37%
IPO
3.32%
Name
CanSino Biologics Inc
Chart & Performance
P/E
—
P/S
28.85
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.49%
Rev. gr., 5y
213.94%
Revenues
345m
-66.52%
Net income
-1.48b
L+53.69%
CFO
-908m
L-51.88%
Dividend
Jul 13, 20220.93727 HKD/sh
Profile
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 345,182 -66.52% | 1,031,041 -76.02% | ||||||
Cost of revenue | 2,507,036 | 2,540,585 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (2,161,854) | (1,509,544) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (11,451) | (219,244) | ||||||
Tax Rate | ||||||||
NOPAT | (2,150,402) | (1,290,300) | ||||||
Net income | (1,482,732) 53.69% | (964,757) -150.40% | ||||||
Dividends | (3,628) | (193,932) | ||||||
Dividend yield | 0.06% | 1.18% | ||||||
Proceeds from repurchase of equity | (150,169) | |||||||
BB yield | 0.91% | |||||||
| Debt | ||||||||
Debt current | 1,459,498 | 1,624,335 | ||||||
Long-term debt | 1,480,659 | 1,323,340 | ||||||
Deferred revenue | 204,998 | |||||||
Other long-term liabilities | 225,209 | (878,008) | ||||||
Net debt | 446,603 | (497,264) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (908,228) | (1,887,599) | ||||||
CAPEX | (610,470) | (1,075,013) | ||||||
Cash from investing activities | (449,646) | (1,191,955) | ||||||
Cash from financing activities | (7,582) | 854,602 | ||||||
FCF | 840,114 | (3,496,220) | ||||||
| Balance | ||||||||
Cash | 4,119,965 | 5,946,791 | ||||||
Long term investments | (1,626,411) | (2,501,852) | ||||||
Excess cash | 2,476,295 | 3,393,387 | ||||||
Stockholders' equity | (1,298,153) | 669,401 | ||||||
Invested Capital | 9,484,576 | 8,580,102 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 246,766 | 247,022 | ||||||
Price | 23.55 -64.72% | 66.75 -62.96% | ||||||
Market cap | 5,811,339 -64.76% | 16,488,718 -63.02% | ||||||
EV | 6,270,930 | 16,488,966 | ||||||
EBITDA | (1,892,800) | (1,313,184) | ||||||
EV/EBITDA | ||||||||
Interest | 64,145 | 41,341 | ||||||
Interest/NOPBT | ||||||||